Spironolactone ameliorates arterial medial calcification in uremic rats: The role of mineralocorticoid receptor signaling in vascular calcification

American Journal of Physiology - Renal Physiology

Volumn 309, Issue 11, 2015, Pages F967-F979

  Tatsumoto, Narihito ^a   Yamada, Shunsuke ^a,b   Tokumoto, Masanori ^b   Eriguchi, Masahiro ^a   Noguchi, Hideko ^a   Torisu, Kumiko ^a   Tsuruya, Kazuhiko ^a   Kitazono, Takanari ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA DENTAL COLLEGE   (Japan)

Author keywords

Chronic kidney disease; Hyperphosphatemia; Mineralocorticoid receptor; Spironolactone; Vascular calcification

Indexed keywords

ADENINE; CALCIUM; CREATININE; MINERALOCORTICOID RECEPTOR; PHOSPHATE; POTASSIUM; PROTEIN; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SODIUM PHOSPHATE COTRANSPORTER; SPIRONOLACTONE; BIOLOGICAL MARKER; MINERALOCORTICOID ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AORTA; APOPTOSIS; ARTERY CALCIFICATION; ARTICLE; BLOOD BIOCHEMISTRY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; HOMEOSTASIS; HYPERKALEMIA; HYPERPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; INTERSTITIAL NEPHRITIS; KIDNEY FUNCTION; MINERAL METABOLISM; NEPHRITIS; NONHUMAN; OXIDATIVE STRESS; PHYSICAL PARAMETERS; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; UREMIA; WESTERN BLOTTING; ABDOMINAL AORTA; ANIMAL; AORTIC DISEASES; BLOOD; BONE DEVELOPMENT; CHEMICALLY INDUCED; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; HUMAN; KIDNEY; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPRAGUE DAWLEY RAT; TIME; TUNICA MEDIA; VASCULAR CALCIFICATION;

ADENINE; ANIMALS; AORTA, ABDOMINAL; AORTIC DISEASES; APOPTOSIS; BIOMARKERS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERPHOSPHATEMIA; KIDNEY; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; OSTEOGENESIS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; SPIRONOLACTONE; TIME FACTORS; TUNICA MEDIA; UREMIA; VASCULAR CALCIFICATION;

EID: 84949224357     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00669.2014     Document Type: Article

References (49)

1. Adijiang A, Higuchi Y, Nishijima F, Shimizu H, Niwa T. Indoxyl sulfate, a uremic toxin, promotes cell senescence in aorta of hypertensive rats. Biochem Biophys Res Commun 399: 637-641, 2010.
2. Aoshima Y, Mizobuchi M, Ogata H, Kumata C, Nakazawa A, Kondo F, Ono N, Koiwa F, Kinugasa E, Akizawa T. Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF-a. Nephrol Dial Transplant 27: 1800-1806, 2012.
3. Bennett WM, Walker RG, Kincaid-Smith P. Renal cortical interstitial volume in mesangial IgA nephropathy. Dissociation from creatinine clearance in serially biopsied patients. Lab Invest 47: 330-335, 1982.
4. Bhan I, Thadhani R. Vascular calcification and ESRD: a hard target. Clin JAm Soc Nephrol 4, Suppl 1: S102-S105, 2009.
5. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38: 938-942, 2001.
6. Borst O, Schaub M, Walker B, Schmid E, Munzer P, Voelkl J, Alesutan I, Rodriguez JM, Vogel S, Schoenberger T, Metzger K, Rath D, Umbach A, Kuhl D, Muller II, Seizer P, Geisler T, Gawaz M, Lang Pivotal role of serum- and glucocorticoid-inducible kinase 1 in vascular inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 35: 547-557, 2015.
7. Briet M, Schiffrin EL. Vascular actions of aldosterone. J Vasc Res 50: 89-99, 2013.
8. Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 9: 459-469, 2013.
9. Chan AK, Sanderson JE, Wang T, Lam W, Yip G, Wang M, Lam YY, Zhang Y, Yeung L, Wu EB, Chan WW, Wong JT, So N, Yu CM. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol 50: 591-596, 2007.
10. Chen H, Sun F, Zhong X, Shao Y, Yoshimura A, Liu Y. Eplerenone- mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. Kidney Blood Press Res 37: 557-566, 2013.
11. Cheng J, Truong LD, Wu X, Kuhl D, Lang F, Du J. Serum- and glucocorticoid-regulated kinase 1 is upregulated following unilateral ureteral obstruction causing epithelial-mesenchymal transition. Kidney Int 78: 668-678, 2010.
12. Feria I, Pichardo I, Juarez P, Ramirez V, Gonzalez MA, Uribe N, Garcfa-Torres R, Lopez-Casillas F, Gamba G, Bobadilla NA. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 63: 43-52, 2003.
13. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 109, Suppl: S81-S96, 2002.
14. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 15: 2959-2964, 2004.
15. Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 72: 1493-505, 2006.
16. Gonzalez M, Martinez R, Amador C, Michea L. Regulation of the sodium-phosphate cotransporter Pit-1 and its role in vascular calcification. Curr Vasc Pharmacol 7: 506-512, 2009.
17. Ikeda H, Tsuruya K, Toyonaga J, Masutani K, Hayashida H, Hi- rakata H, Iida M. Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. Kidney Int 75: 147-155, 2009.
18. Iijima K, Ito Y, Son BK, Akishita M, Ouchi Y. Pravastatin and olmesartan synergistically ameliorate renal failure-induced vascular calcification. J Atheroscler Thromb 21: 917-29, 2014.
19. Jaffe IZ, Tintut Y, Newfell BG, Demer LL, Mendelsohn ME. Miner- alocorticoid receptor activation promotes vascular cell calcification. Arterioscler Thromb Vasc Biol 27: 799-805, 2007.
20. Katsumata K, Kusano K, Hirata M, Tsunemi K, Nagano N, Burke SK, Fukushima N. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 64: 441-450, 2003.
21. Kawata T, Nagano N, Obi M, Miyata S, Koyama C, Kobayashi N, Wakita S, Wada M. Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int 74: 1270-1277, 2008.
22. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18: 1731-1740, 2003.
23. Lundberg E, Fagerberg L, Klevebring D, Matic I, Geiger T, Cox J, Algenas C, Lundeberg J, Mann M, Uhlen M. Defining the transcriptome and proteome in three functionally different human cell lines. Mol Syst Biol 6: 450, 2010.
24. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 19: 1509-1519, 2008.
25. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 350: 256-265, 2012.
26. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 20: 1453-1464, 2009.
27. Namsolleck P, Unger T. Aldosterone synthase inhibitors in cardiovascular and renal diseases. Nephrol Dial Transplant 29, Suppl 1: i62-i68, 2014.
28. Newfell BG, Iyer LK, Mohammad NN, McGraw AP, Ehsan A, Rosano Huang PL, Mendelsohn ME, Jaffe IZ. Aldosterone regulates vascular gene transcription via oxidative stress-dependent and -independent pathways. Arterioscler Thromb Vasc Biol 31: 1871-1880, 2011.
29. Nitta K, Akiba T, Nihei H. Aldosterone blockade and vascular calcification in hemodialysis patients. Am J Med 115: 250, 2003.
30. Ohnishi M, Nakatani T, Lanske B, Razzaque MS. In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin d levels. Circ Cardiovasc Genet 2: 583-590, 2009.
31. Perez-Rojas J, Blanco JA, Cruz C, Trujillo J, Vaidya VS, Uribe N, Bonventre JV, Gamba G, Bobadilla NA. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 292: F131-F139, 2007.
32. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717, 1999.
33. Rautureau Y, Paradis P, Schiffrin EL. Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids 76: 834-839, 2011.
34. Sarafidis PA, Ruilope LM. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? Kidney Int 85: 536-546, 2014.
35. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 109: 697-711, 2011.
36. Terada Y, Kuwana H, Kobayashi T, Okado T, Suzuki N, Yoshimoto T, Hirata Y, Sasaki S. Aldosterone-stimulated SGK1 activity mediates profibrotic signaling in the mesangium. J Am Soc Nephrol 19: 298-309, 2008.
37. Vallon V, Wulff P, Huang DY, Loffing J, Volkl H, Kuhl D, Lang F. Role of Sgk1 in salt and potassium homeostasis. Am J Physiol Regul Integr Comp Physiol 288: R4-R10, 2005.
38. Vallon V, Wyatt AW, Klingel K, Huang DY, Hussain A, Berchtold S, Friedrich B, Grahammer F, Belaiba RS, Gorlach A, Wulff P, Daut J, Dalton ND, Ross J Jr, Flogel U, Schrader J, Osswald H, Kandolf R, Kuhl D, Lang F. SGK1-dependent cardiac CTGF formation and fibrosis following DOCA treatment. J Mol Med (Berl) 84: 396-404, 2006.
39. Vizzardi E, D’Aloia A, Giubbini R, Bordonali T, Bugatti S, Pezzali N, Romeo A, Dei Cas A, Metra M, Dei Cas L. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. Am J Cardiol 106: 1292-1296, 2010.
40. Voelkl J, Alesutan I, Leibrock CB, Quintanilla-Martinez L, Kuhn V, Feger M, Mia S, Ahmed MS, Rosenblatt KP, Kuro OM, Lang F. Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J Clin Invest 123: 812-822, 2013.
41. Wei Y, Whaley-Connell AT, Habibi J, Rehmer J, Rehmer N, Patel K, Hayden M, DeMarco V, Ferrario CM, Ibdah JA, Sowers JR. Miner- alocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension 53: 158-165, 2009.
42. Wu M, Rementer C, Giachelli CM. Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int 93: 365-373, 2013.
43. Wu SY, Yu YR, Cai Y, Jia LX, Wang X, Xiao CS, Tang CS, Qi YF. Endogenous aldosterone is involved in vascular calcification in rat. Exp Biol Med (Maywood) 237: 31-37, 2012.
44. Yamada S, Taniguchi M, Tokumoto M, Toyonaga J, Fujisaki K, Suehiro T, Noguchi H, Iida M, Tsuruya K, Kitazono T. The antioxidant tempol ameliorates arterial medial calcification in uremic rats: important role of oxidative stress in the pathogenesis of vascular calcification in chronic kidney disease. J Bone Miner Res 27: 474-485, 2012.
45. Yamada S, Tokumoto M, Tatsumoto N, Taniguchi M, Noguchi H, Nakano T, Masutani K, Ooboshi H, Tsuruya K, Kitazono T. Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia. Am J Physiol Renal Physiol 306: F1418-F1428, 2014.
46. Yokozawa T, Zheng PD, Oura H, Koizumi F. Animal model of adenine-induced chronic renal failure in rats. Nephron 44: 230-234, 1986.
47. Zhang L, Cui R, Cheng X, Du J. Antiapoptotic effect of serum and glucocorticoid-inducible protein kinase is mediated by novel mechanism activating IkappaB kinase. Cancer Res 65: 457-464, 2005.
48. Zhao G, Xu MJ, Zhao MM, Dai XY, Kong W, Wilson GM, Guan Y, Wang CY, Wang X. Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expression. Kidney Int 82: 34-44, 2012.
49. Zhong W, Oguljahan B, Xiao Y, Nelson J, Hernandez L, Garcia- Barrio M, Francis SC. Serum and glucocorticoid-regulated kinase 1 promotes vascular smooth muscle cell proliferation via regulation of p-catenin dynamics. Cell Signal 26: 2765-2772, 2014.